June 28, 2019
Announcement no. 10

Changes in number of shares and votes

Completion of share capital increase

The Board of Directors of BioPorto A/S (“BioPorto”) decided on June 17, 2019 to partially exercise the authorization in article 16b of the company’s Articles of Association to issue 9,256,577 new shares in a private placement to a limited number of domestic and international shareholders, institutional and financial investors (company announcement no. 8 of June 17, 2019).

Completion of the issue

BioPorto has now received the full subscription amount and the capital increase of in total nominally DKK 9,256,577 has been registered and completed with the Danish Business Authority.

BioPorto’s gross proceeds from the issue will amount to DKK 36,748,610 equivalent to USD 5.5 million. The aggregate net proceeds are expected to amount to DKK 36,013,610 after deduction of costs. The new shares are equivalent to 5.59% of BioPorto’s registered share capital prior to the share capital increase and is exempt from the requirement to publish a prospectus.

Admission to trading and official listing

The new shares have the same rights as the existing shares. The new shares are entitled to dividend from the time when the share capital increase is registered with the Danish Business Authority. The new shares will as soon as possible be admitted to trading and official listing on Nasdaq Copenhagen A/S under the ISIN code of the company’s existing shares (ISIN DK0011048619).

Share Capital and Votes

Pursuant to section 32 of the Danish Capital Markets Act, BioPorto’s nominal share capital amounts to DKK 174,944,375 consisting of 174,944,375 shares of DKK 1.00 equivalent to 174,944,375 votes. BioPorto’s Articles of Association have been updated accordingly and are available on the company’s website.

For further information, please contact:
Peter Mørch Eriksen, CEO
Ole Larsen, CFO
Telephone +45 4529 0000, e-mail: investor@bioporto.com

About BioPorto

BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. BioPorto has its headquarters in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange.